메뉴 건너뛰기




Volumn 9, Issue 4, 1998, Pages 291-310

Antiparkinsonian agents: Clinically significant drug interactions and adverse effects, and their management

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENSERAZIDE; BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; CLOZAPINE; COTRIMOXAZOLE; CYCLOPENTHIAZIDE; DOPAMINE RECEPTOR STIMULATING AGENT; HYDROCHLOROTHIAZIDE; LEVODOPA; LISURIDE; LOXAPINE; MOLINDONE; MONOAMINE OXIDASE INHIBITOR; NITROPRUSSIDE SODIUM; PERGOLIDE; PHENOTHIAZINE DERIVATIVE; PHYSOSTIGMINE; PRAMIPEXOLE; PYRIDOXINE; RESERPINE; RISPERIDONE; ROPINIROLE; SELEGILINE; TETRABENAZINE; TIOTIXENE; UNINDEXED DRUG;

EID: 0031917997     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199809040-00005     Document Type: Article
Times cited : (10)

References (131)
  • 1
    • 0001817958 scopus 로고
    • Epidemiology of movement disorders
    • Marsden CD, Fahn S, editors. London: Butterworths
    • Schoenberg BS. Epidemiology of movement disorders. In: Marsden CD, Fahn S, editors. Movement disorders 2. London: Butterworths, 1987: 17-32
    • (1987) Movement Disorders , vol.2 , pp. 17-32
    • Schoenberg, B.S.1
  • 2
    • 0027889327 scopus 로고
    • Medication use by the elderly
    • Stockton P, Jones JK. Medication use by the elderly. Aging Clin Exp Res 1993; 5 (5): 337-47
    • (1993) Aging Clin Exp Res , vol.5 , Issue.5 , pp. 337-347
    • Stockton, P.1    Jones, J.K.2
  • 3
    • 0030798539 scopus 로고    scopus 로고
    • Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen
    • Wynalda MA, Wienkers LC. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos 1997; 25: 1211-4
    • (1997) Drug Metab Dispos , vol.25 , pp. 1211-1214
    • Wynalda, M.A.1    Wienkers, L.C.2
  • 4
    • 0029994771 scopus 로고    scopus 로고
    • Antiparkinsonian agents: Drug interactions of clinical significance
    • Pfeiffer RF. Antiparkinsonian agents: drug interactions of clinical significance. Drug Saf 1996; 14 (5): 343-54
    • (1996) Drug Saf , vol.14 , Issue.5 , pp. 343-354
    • Pfeiffer, R.F.1
  • 6
    • 0014208039 scopus 로고
    • Aromatic amino acids and modification of parkinsonism
    • Cotzias GC, van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374-9
    • (1967) N Engl J Med , vol.276 , pp. 374-379
    • Cotzias, G.C.1    Van Woert, M.H.2    Schiffer, L.M.3
  • 7
    • 0026668120 scopus 로고
    • Anticholinergic effects of drugs commonly prescribed for the elderly: Potential means for assessing risk of delirium
    • Tune L, Carr S, Hong E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992; 149: 1393-4
    • (1992) Am J Psychiatry , vol.149 , pp. 1393-1394
    • Tune, L.1    Carr, S.2    Hong, E.3
  • 8
    • 0017225588 scopus 로고
    • Effect of anticholinergic drugs on gastrointestinal absorption of L-dopa in rats and in man
    • Algeri S, Cerletti C, Curcio M, et al. Effect of anticholinergic drugs on gastrointestinal absorption of L-dopa in rats and in man. Eur J Pharmacol 1976; 35: 293-9
    • (1976) Eur J Pharmacol , vol.35 , pp. 293-299
    • Algeri, S.1    Cerletti, C.2    Curcio, M.3
  • 9
    • 0029928467 scopus 로고    scopus 로고
    • The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers
    • Roberts J, Waller DG, von Renwick AG, et al. The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. Br J Clin Pharmacol 1996; 41: 331-7
    • (1996) Br J Clin Pharmacol , vol.41 , pp. 331-337
    • Roberts, J.1    Waller, D.G.2    Von Renwick, A.G.3
  • 11
    • 0021823653 scopus 로고
    • Pharmacologic changes in dopaminergic systems induced by long term administration of amantadine
    • Gianutsos G, Chute S, Dunn JP. Pharmacologic changes in dopaminergic systems induced by long term administration of amantadine. Eur J Pharmacol 1985; 110: 357-61
    • (1985) Eur J Pharmacol , vol.110 , pp. 357-361
    • Gianutsos, G.1    Chute, S.2    Dunn, J.P.3
  • 12
    • 0017181731 scopus 로고
    • Anticholinergic and membrane activities of amantadine in neuromuscular transmission
    • Nastuck WC, Su PC, Doublet P. Anticholinergic and membrane activities of amantadine in neuromuscular transmission. Nature 1976; 264: 76-9
    • (1976) Nature , vol.264 , pp. 76-79
    • Nastuck, W.C.1    Su, P.C.2    Doublet, P.3
  • 13
    • 0026751312 scopus 로고
    • Amantadine as N-methyl-D-aspartic acid receptor antagonist: New possibilities for therapeutic applications?
    • Stoof JC, Booij J, Drukarch B. Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? Clin Neurol 1992; 94 Suppl.: S4-6
    • (1992) Clin Neurol , vol.94 , Issue.SUPPL.
    • Stoof, J.C.1    Booij, J.2    Drukarch, B.3
  • 14
    • 0029688949 scopus 로고    scopus 로고
    • Amantadine-induced vocal myoclonus
    • Pfeiffer RF. Amantadine-induced vocal myoclonus [letter]. Mov Disord 1996; 11 (1): 104-51
    • (1996) Mov Disord , vol.11 , Issue.1 , pp. 104-151
    • Pfeiffer, R.F.1
  • 15
    • 0013832252 scopus 로고
    • Absorption, distribution, and excretion of amantadine hydrochloride
    • Bleidner WE, Harman JB, Hewes WE, et al. Absorption, distribution, and excretion of amantadine hydrochloride. J Pharmacol Exp Ther 1965; 150: 484-90
    • (1965) J Pharmacol Exp Ther , vol.150 , pp. 484-490
    • Bleidner, W.E.1    Harman, J.B.2    Hewes, W.E.3
  • 16
    • 0024846923 scopus 로고
    • Case report: Toxic delirium in a patient taking amantadine and trimethopim-sulfamethoxazole
    • Speeg KV, Leighton JA, Maldonoado AL. Case report: toxic delirium in a patient taking amantadine and trimethopim-sulfamethoxazole. Am J Med Sci 1989; 298: 410-2
    • (1989) Am J Med Sci , vol.298 , pp. 410-412
    • Speeg, K.V.1    Leighton, J.A.2    Maldonoado, A.L.3
  • 17
    • 0021028081 scopus 로고
    • Amantadine-dyazide interaction
    • Wilson TW, Rajput AH. Amantadine-dyazide interaction. Can Med Assoc J 1983; 129: 974-5
    • (1983) Can Med Assoc J , vol.129 , pp. 974-975
    • Wilson, T.W.1    Rajput, A.H.2
  • 18
    • 0026094867 scopus 로고
    • Bromocriptine-associated headache: Possible life-threatening sympathomimetic reaction
    • Kulig K, Moore LL, Kirk M, et al. Bromocriptine-associated headache: possible life-threatening sympathomimetic reaction. Obst Gynecol 1991; 78: 941-3
    • (1991) Obst Gynecol , vol.78 , pp. 941-943
    • Kulig, K.1    Moore, L.L.2    Kirk, M.3
  • 19
    • 0025324182 scopus 로고
    • Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine in normal subjects
    • Nelson MV, Berchou RC, Kareti D, et al. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine in normal subjects [abstract]. Clin Pharmacol Ther 1990; 47: 166
    • (1990) Clin Pharmacol Ther , vol.47 , pp. 166
    • Nelson, M.V.1    Berchou, R.C.2    Kareti, D.3
  • 20
    • 2442740655 scopus 로고
    • Enhancement of bromocriptine clinical effect and plasma levels with erythromycin
    • Sibley WA, Laguna JF. Enhancement of bromocriptine clinical effect and plasma levels with erythromycin. Excerpta Med 1981; 548: 329-30
    • (1981) Excerpta Med , vol.548 , pp. 329-330
    • Sibley, W.A.1    Laguna, J.F.2
  • 21
    • 0018854781 scopus 로고
    • Alcohol increases bromocriptine side effects
    • Ayres J, Maseley MN. Alcohol increases bromocriptine side effects [letter]. N Engl J Med 1980; 302: 806
    • (1980) N Engl J Med , vol.302 , pp. 806
    • Ayres, J.1    Maseley, M.N.2
  • 22
    • 0017596822 scopus 로고
    • Metabolic and clinical studies on patients with acromegaly treated with bromocriptine over 22 months
    • Schwinn G, Dirks H, McIntosh C, et al. Metabolic and clinical studies on patients with acromegaly treated with bromocriptine over 22 months. Eur J Clin Invest 1977; 7: 101-7
    • (1977) Eur J Clin Invest , vol.7 , pp. 101-107
    • Schwinn, G.1    Dirks, H.2    McIntosh, C.3
  • 23
    • 0017694704 scopus 로고
    • Sodium nitroprusside and epidural blockade to treat severe ergotism
    • Andersen PK, Christensen KN, Hole P, et al. Sodium nitroprusside and epidural blockade to treat severe ergotism. N Engl J Med 1977; 296: 1271-3
    • (1977) N Engl J Med , vol.296 , pp. 1271-1273
    • Andersen, P.K.1    Christensen, K.N.2    Hole, P.3
  • 24
    • 0025317247 scopus 로고
    • Pergolide: A review of its pharmacological properties and therapeutic potential in Parkinson's disease
    • Langtry HD, Clissold SP. Pergolide: a review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs 1990; 39: 491-506
    • (1990) Drugs , vol.39 , pp. 491-506
    • Langtry, H.D.1    Clissold, S.P.2
  • 25
    • 0029958441 scopus 로고    scopus 로고
    • High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum
    • Piercey ME, Walker EL, Feldpausch DL, et al. High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum. Neurosci Let 1996; 219: 138-40
    • (1996) Neurosci Let , vol.219 , pp. 138-140
    • Piercey, M.E.1    Walker, E.L.2    Feldpausch, D.L.3
  • 26
    • 0030753601 scopus 로고    scopus 로고
    • Clinical evaluation of pramipexole in advanced Parkinson's disease
    • Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease. Neurology 1997; 49: 162-8
    • (1997) Neurology , vol.49 , pp. 162-168
    • Lieberman, A.1    Ranhosky, A.2    Korts, D.3
  • 27
    • 0343770946 scopus 로고    scopus 로고
    • Kalamazoo (MI): Pharmacia and Upjohn Co., Jun
    • Pharmacia and Upjohn Co. Mirapex package insert. Kalamazoo (MI): Pharmacia and Upjohn Co., Jun 1997
    • (1997) Mirapex Package Insert
  • 28
    • 0343335098 scopus 로고    scopus 로고
    • Crawley. UK: SmithKline Beecham, Sep
    • SmithKline Beecham. Requip package insert. Crawley. UK: SmithKline Beecham, Sep 1997
    • (1997) Requip Package Insert
  • 29
    • 0030804074 scopus 로고    scopus 로고
    • Ropinirole for the treatment of early Parkinson's disease
    • Adler CH, Sethi KD, Davis TL, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997; 49: 393-9
    • (1997) Neurology , vol.49 , pp. 393-399
    • Ch, A.1    Sethi, K.D.2    Davis, T.L.3
  • 30
    • 0003979209 scopus 로고    scopus 로고
    • SmithKline Beecham
    • Data on file, SmithKline Beecham
    • Data on File
  • 31
    • 0001560527 scopus 로고    scopus 로고
    • A multicenter double blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease
    • Kreider MS, Knox S, Gardiner D, et al. A multicenter double blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease [abstract]. Neurology 1996; 46: A475
    • (1996) Neurology , vol.46
    • Kreider, M.S.1    Knox, S.2    Gardiner, D.3
  • 32
    • 0014635062 scopus 로고
    • Pyridoxine reversal of L-dopa effects in parkinsonism
    • Duvoisin RC, Yahr MD, Cote LD. Pyridoxine reversal of L-dopa effects in parkinsonism [letter]. Trans Am Neurol Ass 1969; 94: 81
    • (1969) Trans Am Neurol Ass , vol.94 , pp. 81
    • Duvoisin, R.C.1    Yahr, M.D.2    Cote, L.D.3
  • 33
    • 0023265840 scopus 로고
    • 3-O-methyldopa and the response to levodopa in Parkinson's disease
    • Nutt JG, Woodward WR, Gancher ST, et al. 3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 1987; 21: 584-8
    • (1987) Ann Neurol , vol.21 , pp. 584-588
    • Nutt, J.G.1    Woodward, W.R.2    Gancher, S.T.3
  • 34
    • 0026526135 scopus 로고
    • Levodopa: Pharmacology, pharmacokinetics and pharmacodynamics
    • Juncos JJ. Levodopa: pharmacology, pharmacokinetics and pharmacodynamics. Neurol Clin North Am 1992; 10: 487-509
    • (1992) Neurol Clin North Am , vol.10 , pp. 487-509
    • Juncos, J.J.1
  • 35
    • 0015374287 scopus 로고
    • The effect of an antacid administration on the absorption and metabolism of levodopa
    • Leon AS, Spiegel HE. The effect of an antacid administration on the absorption and metabolism of levodopa. J Clin Pharmacol New Drugs 1972; 12: 263-7
    • (1972) J Clin Pharmacol New Drugs , vol.12 , pp. 263-267
    • Leon, A.S.1    Spiegel, H.E.2
  • 36
    • 0023634716 scopus 로고
    • Single dose pharmacokinetics of Madopar HBS in patients and the effect of food and antacid on the absorption of Madopar HBS in volunteers
    • Malcolm SL, Allen JG, Bird H, et al. Single dose pharmacokinetics of Madopar HBS in patients and the effect of food and antacid on the absorption of Madopar HBS in volunteers. Eur Neurol 1987; 27: 28-35
    • (1987) Eur Neurol , vol.27 , pp. 28-35
    • Malcolm, S.L.1    Allen, J.G.2    Bird, H.3
  • 38
    • 0024600260 scopus 로고
    • Ferrous sulfate reduces levodopa bioavailability: Chelation as a possible mechanism
    • Campbell NRC, Hasinoff B. Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. Clin Pharmacol Ther 1989; 45: 220-5
    • (1989) Clin Pharmacol Ther , vol.45 , pp. 220-225
    • Campbell, N.R.C.1    Hasinoff, B.2
  • 39
    • 0025149525 scopus 로고
    • Sinemet-ferrous sulphate interaction in patients with Parkinson's disease
    • Campbell NRC, Rankine D, Goodridge AE, et al. Sinemet-ferrous sulphate interaction in patients with Parkinson's disease. Br J Clin Pharmacol 1990; 30: 599-605
    • (1990) Br J Clin Pharmacol , vol.30 , pp. 599-605
    • Campbell, N.R.C.1    Rankine, D.2    Goodridge, A.E.3
  • 40
    • 0018819764 scopus 로고
    • Interacticm of levodopa and metoclopramide on gastric emptying
    • Berkowitz DM, McCallum RW. Interacticm of levodopa and metoclopramide on gastric emptying. Clin Pharmacol Ther 1980; 27: 415-20
    • (1980) Clin Pharmacol Ther , vol.27 , pp. 415-420
    • Berkowitz, D.M.1    McCallum, R.W.2
  • 41
    • 0007367712 scopus 로고
    • Parkinsonism occurring with methyldopa treatment
    • Groden BM. Parkinsonism occurring with methyldopa treatment [letter]. BMJ 1963; 2: 1001
    • (1963) BMJ , vol.2 , pp. 1001
    • Groden, B.M.1
  • 42
    • 7144221653 scopus 로고
    • Parkinsonism associated with alpha-methyldopa therapy
    • Peastin MJT. Parkinsonism associated with alpha-methyldopa therapy [letter]. BMJ 1964; 2: 168
    • (1964) BMJ , vol.2 , pp. 168
    • Peastin, M.J.T.1
  • 43
    • 0014031392 scopus 로고
    • Parkinsonism occurring during methyldopa therapy
    • Strang RR. Parkinsonism occurring during methyldopa therapy. Can Med Assoc J 1966; 95: 928-9
    • (1966) Can Med Assoc J , vol.95 , pp. 928-929
    • Strang, R.R.1
  • 44
    • 0019128272 scopus 로고
    • Exacerbation of parkinsonism by methyldopa
    • Rosenblum AM, Montgomery EB. Exacerbation of parkinsonism by methyldopa. J Am Med 1980; 244: 2727-8
    • (1980) J Am Med , vol.244 , pp. 2727-2728
    • Rosenblum, A.M.1    Montgomery, E.B.2
  • 45
    • 0015922966 scopus 로고
    • Interaction between levodopa and methyldopa
    • Gibberd FB, Small E. Interaction between levodopa and methyldopa. BMJ 1973; 2: 90-1
    • (1973) BMJ , vol.2 , pp. 90-91
    • Gibberd, F.B.1    Small, E.2
  • 46
    • 0017256736 scopus 로고
    • Clonidine and the antiparkinsonian response to L-dopa or piribedil
    • Shoulson I, Chase TN. Clonidine and the antiparkinsonian response to L-dopa or piribedil. Neuropharmacolouy 1976; 15: 25-7
    • (1976) Neuropharmacolouy , vol.15 , pp. 25-27
    • Shoulson, I.1    Chase, T.N.2
  • 47
    • 0015736359 scopus 로고
    • Interactions between levodopa and other drugs: Significance in the treatment of Parkinson's disease
    • Bianchine JR, Sunyapridakul L. Interactions between levodopa and other drugs: significance in the treatment of Parkinson's disease. Drugs 1973; 6: 364-88
    • (1973) Drugs , vol.6 , pp. 364-388
    • Bianchine, J.R.1    Sunyapridakul, L.2
  • 48
    • 0021332879 scopus 로고
    • Adverse reactions due to dopamine blockade by amoxapine
    • Hunt-Fugate AK, Zander J, Lesar TS. Adverse reactions due to dopamine blockade by amoxapine. Pharmacotherapy 1984; 4: 35-9
    • (1984) Pharmacotherapy , vol.4 , pp. 35-39
    • Hunt-Fugate, A.K.1    Zander, J.2    Lesar, T.S.3
  • 49
    • 0017863880 scopus 로고
    • Deprenyl administration in man: A selective monoamine oxidase inhibitor without the 'cheese effect'
    • Elsworth JD, Glover V, Reynolds GP, et al. Deprenyl administration in man: a selective monoamine oxidase inhibitor without the 'cheese effect'. Psychopharmacolopy 1978; 57: 33-8
    • (1978) Psychopharmacolopy , vol.57 , pp. 33-38
    • Elsworth, J.D.1    Glover, V.2    Reynolds, G.P.3
  • 50
    • 0019992365 scopus 로고
    • Adverse interaction of levodopa with tricyclic antidepressanls
    • Edwards M. Adverse interaction of levodopa with tricyclic antidepressanls. Practitioner 1982; 226: 1448-9
    • (1982) Practitioner , vol.226 , pp. 1448-1449
    • Edwards, M.1
  • 51
    • 0016743254 scopus 로고
    • Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man
    • Morgan JP, Riviera-Calimlim L, Messiha F, et al. Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man. Neurology 1975; 25: 1029-34
    • (1975) Neurology , vol.25 , pp. 1029-1034
    • Morgan, J.P.1    Riviera-Calimlim, L.2    Messiha, F.3
  • 52
    • 0026515520 scopus 로고
    • Impaired levodopa response in Parkinson's disease during melanoma therapy
    • Merello M, Esteguy M, Perazzo F, et al. Impaired levodopa response in Parkinson's disease during melanoma therapy. Clin Neuropharmacol 1992; 15: 69-74
    • (1992) Clin Neuropharmacol , vol.15 , pp. 69-74
    • Merello, M.1    Esteguy, M.2    Perazzo, F.3
  • 53
    • 0026515520 scopus 로고
    • Impaired levodopa response in Parkinson's Disease during melanoma therapy
    • Merello M, Esteguy M, Perazzo F, et al. Impaired levodopa response in Parkinson's Disease during melanoma therapy. Clin Neuropharmacol 1992; 15: 69-74
    • (1992) Clin Neuropharmacol , vol.15 , pp. 69-74
    • Merello, M.1    Esteguy, M.2    Perazzo, F.3
  • 54
    • 0026628657 scopus 로고
    • Effect of a macrolide (spiramycin) on the pharmacokinetics of L-dopa and carbidopa in healthy volunteers
    • Brion N, Kollenbach K, Marion MH, et al. Effect of a macrolide (spiramycin) on the pharmacokinetics of L-dopa and carbidopa in healthy volunteers. Clin Neuropharmacol 1992; 15: 229-35
    • (1992) Clin Neuropharmacol , vol.15 , pp. 229-235
    • Brion, N.1    Kollenbach, K.2    Marion, M.H.3
  • 55
    • 0027494763 scopus 로고
    • Effect of D-penicillamine on pharmacokinetics of levodopa in Parkinson's disease
    • Mizuta E, Kuno S. Effect of D-penicillamine on pharmacokinetics of levodopa in Parkinson's disease Clin Neuropharmacol 1943; 16: 448-50
    • (1943) Clin Neuropharmacol , vol.16 , pp. 448-450
    • Mizuta, E.1    Kuno, S.2
  • 57
    • 0015983689 scopus 로고
    • Levodopa-propranolol therapy in parkinsonian tremor
    • Kissel P, Tridon P, Andre JM. Levodopa-propranolol therapy in parkinsonian tremor [letter]. Lancet 1974; 1: 403-4
    • (1974) Lancet , vol.1 , pp. 403-404
    • Kissel, P.1    Tridon, P.2    Andre, J.M.3
  • 58
    • 0002859737 scopus 로고
    • Adverse effects of levodopa
    • Olanow CW, Lieberman AN, editors. Park Ridge (NJ): Parthenon
    • Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, editors. The scientific basis for the treatment of Parkinson's disease. Park Ridge (NJ): Parthenon, 1992: 89-112
    • (1992) The Scientific Basis for the Treatment of Parkinson's Disease , pp. 89-112
    • Fahn, S.1
  • 59
    • 0029884740 scopus 로고    scopus 로고
    • Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease
    • Carpentier AF, Bonnet AM, Vidailhet M, et al. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology 1996; 46: 1548-51
    • (1996) Neurology , vol.46 , pp. 1548-1551
    • Carpentier, A.F.1    Bonnet, A.M.2    Vidailhet, M.3
  • 60
    • 0016430740 scopus 로고
    • Diphenylhydantoin blocking of levodopa effects
    • Mendez JS, Cotzias GC, Mena I, et al. Diphenylhydantoin blocking of levodopa effects. Arch Neurol 1975; 32: 44-6
    • (1975) Arch Neurol , vol.32 , pp. 44-46
    • Mendez, J.S.1    Cotzias, G.C.2    Mena, I.3
  • 61
    • 0027159879 scopus 로고
    • Oral levodopa/carbidopa solution versus tablets in Parkinson's disease with severe fluctuations: A pilot study
    • Kurth MC, Tetrud JW, Irwin I, et al. Oral levodopa/carbidopa solution versus tablets in Parkinson's disease with severe fluctuations: a pilot study. Neurology 1993; 43: 1036-9
    • (1993) Neurology , vol.43 , pp. 1036-1039
    • Kurth, M.C.1    Tetrud, J.W.2    Irwin, I.3
  • 62
    • 0027518164 scopus 로고
    • Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations
    • Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 1993; 43: 1698-703
    • (1993) Neurology , vol.43 , pp. 1698-1703
    • Kurth, M.C.1    Tetrud, J.W.2    Tanner, C.M.3
  • 63
    • 0029732865 scopus 로고    scopus 로고
    • Liquid levodopa/ carbidopa produces significant improvement in motor function without dyskinesia exacerbation
    • Pappert EJ, Goetz GC, Niederman F, et al. Liquid levodopa/ carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology 1996; 47: 1493-5
    • (1996) Neurology , vol.47 , pp. 1493-1495
    • Pappert, E.J.1    Goetz, G.C.2    Niederman, F.3
  • 64
    • 0027324013 scopus 로고
    • Suppression of dyskinesias in advanced Parkinson's disease: Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms
    • Bennett Jr JP, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease: increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993; 43: 1551-5
    • (1993) Neurology , vol.43 , pp. 1551-1555
    • Bennett Jr., J.P.1    Landow, E.R.2    Schuh, L.A.3
  • 65
    • 0016414699 scopus 로고
    • The potentiation of the anti-akinetic effect after levodopa treatment by an inhibitor of MAO-B, deprenyl
    • Birkmayer W, Riederer P, Youdim MBH, et al. The potentiation of the anti-akinetic effect after levodopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 1975; 36: 303-26
    • (1975) J Neural Transm , vol.36 , pp. 303-326
    • Birkmayer, W.1    Riederer, P.2    Youdim, M.B.H.3
  • 66
    • 0024456653 scopus 로고
    • Effect of deprenyl on the progression of disability in early Parkinson's disease
    • Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364-71
    • (1989) N Engl J Med , vol.321 , pp. 1364-1371
  • 67
    • 0028835283 scopus 로고
    • The effect of selegiline on the peripheral pharmacokinetics of levodopa in young volunteers
    • Roberts J, Waller DG, O'Shea N, et al. The effect of selegiline on the peripheral pharmacokinetics of levodopa in young volunteers. Br J Clin Pharmacol 1995; 40: 404-6
    • (1995) Br J Clin Pharmacol , vol.40 , pp. 404-406
    • Roberts, J.1    Waller, D.G.2    O'Shea, N.3
  • 68
    • 0026469784 scopus 로고
    • The antiparkinsonian effect of deprenyl derives lrom transient improvement that is likely to be symptomatic
    • Schulzer M, Mak E, Calne DB. The antiparkinsonian effect of deprenyl derives lrom transient improvement that is likely to be symptomatic. Ann Neurol 1992; 32: 795-8
    • (1992) Ann Neurol , vol.32 , pp. 795-798
    • Schulzer, M.1    Mak, E.2    Calne, D.B.3
  • 69
    • 0019972555 scopus 로고
    • Possible development of serotonin syndrome in man
    • Insel TR, Roy BF, Cohen RM. Possible development of serotonin syndrome in man. Am J Psychiatry 1982; 139: 954-5
    • (1982) Am J Psychiatry , vol.139 , pp. 954-955
    • Insel, T.R.1    Roy, B.F.2    Cohen, R.M.3
  • 70
    • 0025087863 scopus 로고
    • Interaction of fluoxetine and selegiline
    • Suchowersky O, de Vries JD. Interaction of fluoxetine and selegiline. Can J Psychiatry 1990; 35: 571-2
    • (1990) Can J Psychiatry , vol.35 , pp. 571-572
    • Suchowersky, O.1    De Vries, J.D.2
  • 73
    • 0027500494 scopus 로고
    • Pseudopheochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline
    • Monastruc JL, Chamontin B, Senard JM, et al. Pseudopheochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline [letter]. Lancet 1993; 341: 555
    • (1993) Lancet , vol.341 , pp. 555
    • Monastruc, J.L.1    Chamontin, B.2    Senard, J.M.3
  • 74
    • 0027980832 scopus 로고
    • Fluoxetine and selegiline: Lack of significant interaction
    • Waters CH. Fluoxetine and selegiline: lack of significant interaction. Can J Neurol Sci 1994; 21: 259-61
    • (1994) Can J Neurol Sci , vol.21 , pp. 259-261
    • Waters, C.H.1
  • 76
    • 0026074757 scopus 로고
    • Severe adverse interaction between pethidine and selegiline
    • Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline [letter]. Lancet 1991; 337: 246
    • (1991) Lancet , vol.337 , pp. 246
    • Zornberg, G.L.1    Bodkin, J.A.2    Cohen, B.M.3
  • 77
    • 0023408711 scopus 로고
    • Unusual drug interactions between monamine oxidase inhibitors and tricyclic antidepressants
    • Richards GA, Fritz VU, Pincus P, et al. Unusual drug interactions between monamine oxidase inhibitors and tricyclic antidepressants. J Neurol Neurosurg Psychiatry 1987; 50: 1240-1
    • (1987) J Neurol Neurosurg Psychiatry , vol.50 , pp. 1240-1241
    • Richards, G.A.1    Fritz, V.U.2    Pincus, P.3
  • 78
    • 0023189808 scopus 로고
    • Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction
    • Tackley RM, Tregakis B. Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction. Anesthesia 1987; 42: 760-3
    • (1987) Anesthesia , vol.42 , pp. 760-763
    • Tackley, R.M.1    Tregakis, B.2
  • 79
    • 0027935135 scopus 로고
    • General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase
    • Kaakkola S, Gordin A, Mannisto PT. General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen Pharmacol 1994; 25: 813-24
    • (1994) Gen Pharmacol , vol.25 , pp. 813-824
    • Kaakkola, S.1    Gordin, A.2    Mannisto, P.T.3
  • 80
    • 0027514196 scopus 로고
    • The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers
    • Keranen T, Gordin A, Harjla V-P, et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993; 16: 145-56
    • (1993) Clin Neuropharmacol , vol.16 , pp. 145-156
    • Keranen, T.1    Gordin, A.2    Harjla, V.-P.3
  • 81
    • 0027770982 scopus 로고
    • Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients
    • Roberts JW, Cora-Locatelli G, Bravi D, et al. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1994; 44: 2685-8
    • (1994) Neurology , vol.44 , pp. 2685-2688
    • Roberts, J.W.1    Cora-Locatelli, G.2    Bravi, D.3
  • 82
    • 0025803672 scopus 로고
    • Central action of benserazide after COMT inhibition demonstrated in vivo by PET
    • Tedroff J, Hartvig P, Bjurling P, et al. Central action of benserazide after COMT inhibition demonstrated in vivo by PET. J Neural Transm 1991; 85: 11-7
    • (1991) J Neural Transm , vol.85 , pp. 11-17
    • Tedroff, J.1    Hartvig, P.2    Bjurling, P.3
  • 83
    • 0016829492 scopus 로고
    • Catechol-O-methyltransferase: Pharmacological aspects and physiological role
    • Guldberg HC, Marsden CD. Catechol-O-methyltransferase: pharmacological aspects and physiological role [letter]. Pharmacol Rev 1975; 27: 135-206
    • (1975) Pharmacol Rev , vol.27 , pp. 135-206
    • Guldberg, H.C.1    Marsden, C.D.2
  • 84
    • 0027343947 scopus 로고
    • Treatment of drug-induced psychosis in Parkinson's disease with clozapine
    • Narbayashi H, Nagatsu T, Yangisawa N, et al., editors. New York (NY): Raven Press
    • Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. In: Narbayashi H, Nagatsu T, Yangisawa N, et al., editors. Advances in neurology. New York (NY): Raven Press, 1993: 703-6
    • (1993) Advances in Neurology , pp. 703-706
    • Greene, P.1    Cote, L.2    Fahn, S.3
  • 85
    • 0030819935 scopus 로고    scopus 로고
    • The emerging role of clozapine in the treatment of movement disorders
    • Factor SA, Friedman JM. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997; 12: 483-96
    • (1997) Mov Disord , vol.12 , pp. 483-496
    • Factor, S.A.1    Friedman, J.M.2
  • 87
    • 0024268376 scopus 로고
    • Neuroleptic malignant syndrome after clozapine plus carbamazepine
    • Miller T, Becker T, Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. Lancet 1988; II: 1500
    • (1988) Lancet , vol.2 , pp. 1500
    • Miller, T.1    Becker, T.2    Fritze, J.3
  • 88
    • 0026078295 scopus 로고
    • Effect of phenytoin on plasma clozapine concentrations in two patients
    • Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry 1991; 52: 223-5
    • (1991) J Clin Psychiatry , vol.52 , pp. 223-225
    • Miller, D.D.1
  • 90
    • 0026014569 scopus 로고
    • Possible interactions between clozapine and lorazepam
    • Cobb CD, Anderson CB, Seidel DR. Possible interactions between clozapine and lorazepam. Am J Psychiatry 1991; 148: 1606-7
    • (1991) Am J Psychiatry , vol.148 , pp. 1606-1607
    • Cobb, C.D.1    Anderson, C.B.2    Seidel, D.R.3
  • 91
    • 0026011475 scopus 로고
    • A case report of cimetidine-induced clozapine toxicity
    • Syzmananski S, Lieberman JA, Picou D, et al. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry 1991; 52: 21-2
    • (1991) J Clin Psychiatry , vol.52 , pp. 21-22
    • Syzmananski, S.1    Lieberman, J.A.2    Picou, D.3
  • 92
    • 0024872485 scopus 로고
    • Myoclonus during treatment with clozapine and lithium: The role of serotonin
    • Lemus CZ, Liberman JA, Johns CA. Myoclonus during treatment with clozapine and lithium: the role of serotonin. Hillside J Clin Psychiatry 1989; 11: 127-30
    • (1989) Hillside J Clin Psychiatry , vol.11 , pp. 127-130
    • Lemus, C.Z.1    Liberman, J.A.2    Johns, C.A.3
  • 93
    • 0022458560 scopus 로고
    • Apparent neuroleptic malignant syndrome with clozapine and lithium
    • Pope HG, Cole JO, Choras PT, et al. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986; 174: 493-5
    • (1986) J Nerv Ment Dis , vol.174 , pp. 493-495
    • Pope, H.G.1    Cole, J.O.2    Choras, P.T.3
  • 94
    • 0029845563 scopus 로고    scopus 로고
    • Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease
    • Wolters ECH, Jansen ENH, Tuynman-Qua HG, et al. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996; 47: 1085-7
    • (1996) Neurology , vol.47 , pp. 1085-1087
    • Wolters, E.C.H.1    Jansen, E.N.H.2    Tuynman-Qua, H.G.3
  • 95
    • 0028144914 scopus 로고
    • Risperidone in Parkinson's disease
    • Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease [letter]. Lancet 1994; 344: 681
    • (1994) Lancet , vol.344 , pp. 681
    • Ford, B.1    Lynch, T.2    Greene, P.3
  • 96
    • 0029610790 scopus 로고
    • Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes
    • Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56: 556-9
    • (1995) J Clin Psychiatry , vol.56 , pp. 556-559
    • Rich, S.S.1    Friedman, J.H.2    Ott, B.R.3
  • 98
    • 0023920165 scopus 로고
    • Neuroleptic-induced Parkinson's syndrome: Clinical features and results with levodopa
    • Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results with levodopa. J Neurol Neurosurg Psychiatry 1988; 51: 850-4
    • (1988) J Neurol Neurosurg Psychiatry , vol.51 , pp. 850-854
    • Hardie, R.J.1    Lees, A.J.2
  • 100
    • 0027213299 scopus 로고
    • Unilateral pallidal lesions after acute disulfiram intoxication: A clinical and magnetic resonance study
    • de Mari M, De Blasi R, Lamberti P. Unilateral pallidal lesions after acute disulfiram intoxication: a clinical and magnetic resonance study. Mov Disord 1993; 8: 247-9
    • (1993) Mov Disord , vol.8 , pp. 247-249
    • De Mari, M.1    De Blasi, R.2    Lamberti, P.3
  • 101
    • 0028217518 scopus 로고
    • Chronic lithium neurotoxicity presenting as Parkinson's disease: A cross-sectional study of patients with 15 years or more on lithium
    • Lecamwasam D, Syneck B, Moyles K. Chronic lithium neurotoxicity presenting as Parkinson's disease: a cross-sectional study of patients with 15 years or more on lithium. Int Clin Psychopharmacology 1994; 9: 127-9
    • (1994) Int Clin Psychopharmacology , vol.9 , pp. 127-129
    • Lecamwasam, D.1    Syneck, B.2    Moyles, K.3
  • 102
    • 0026593291 scopus 로고
    • Manganese intoxication during total parenteral nutrition
    • Ejima A, Imamura T, Nakamura S. Manganese intoxication during total parenteral nutrition [letter]. Lancet 1992; 339: 426
    • (1992) Lancet , vol.339 , pp. 426
    • Ejima, A.1    Imamura, T.2    Nakamura, S.3
  • 103
    • 0028089057 scopus 로고
    • Meperidine and reversible Parkinsonism
    • Olive JM, Masana L, Gonzalez J. Meperidine and reversible Parkinsonism. Mov Disord 1994; 9: 115-6
    • (1994) Mov Disord , vol.9 , pp. 115-116
    • Olive, J.M.1    Masana, L.2    Gonzalez, J.3
  • 104
    • 0021360811 scopus 로고
    • Parkinsonian side effects induced by a monoamine oxidase inhibitor
    • Teusink JP, Alexopoulos GS, Shamoian CA. Parkinsonian side effects induced by a monoamine oxidase inhibitor. Am J Psychiatry 1984; 141: 118-9
    • (1984) Am J Psychiatry , vol.141 , pp. 118-119
    • Teusink, J.P.1    Alexopoulos, G.S.2    Shamoian, C.A.3
  • 105
    • 0026729474 scopus 로고
    • Exacerbation of Parkinsonism by tacrine
    • Ott BR, Lannon MC. Exacerbation of Parkinsonism by tacrine. Clin Neuropharmacol 1992; 15: 322-5
    • (1992) Clin Neuropharmacol , vol.15 , pp. 322-325
    • Ott, B.R.1    Lannon, M.C.2
  • 107
    • 0019944931 scopus 로고
    • Metoclopramide-induced parkinsonism
    • Indo T, Ando K. Metoclopramide-induced parkinsonism. Arch Neurol 1982; 39: 494-6
    • (1982) Arch Neurol , vol.39 , pp. 494-496
    • Indo, T.1    Ando, K.2
  • 108
    • 0026500949 scopus 로고
    • Parkinsonian syndrome after long-term treatment with clebopride
    • Montagna P, Gabellini AS, Montari I, et al. Parkinsonian syndrome after long-term treatment with clebopride. Mov Disord 1992; 7: 89-90
    • (1992) Mov Disord , vol.7 , pp. 89-90
    • Montagna, P.1    Gabellini, A.S.2    Montari, I.3
  • 109
    • 0029076276 scopus 로고
    • Effects of calcium antagonists on the dopamine system
    • Mena AM, de Yebenes MJG, Taberno C, et al. Effects of calcium antagonists on the dopamine system. Clin Neuropharmacol 1995; 18: 410-26
    • (1995) Clin Neuropharmacol , vol.18 , pp. 410-426
    • Mena, A.M.1    De Mjg, Y.2    Taberno, C.3
  • 110
    • 0023228052 scopus 로고
    • Flunarizine and cinnarizine-induced extrapyramidal reactions
    • Micheli F, Fernandez Pardel M, Gatto M, et al. Flunarizine and cinnarizine-induced extrapyramidal reactions. Neurology 1987; 37: 881-4
    • (1987) Neurology , vol.37 , pp. 881-884
    • Micheli, F.1    Fernandez Pardel, M.2    Gatto, M.3
  • 112
    • 0024322957 scopus 로고
    • Diltiazem-induced parkinsonism
    • Dick RS, Barold SS. Diltiazem-induced parkinsonism. Am J Med 1989; 87: 95-6
    • (1989) Am J Med , vol.87 , pp. 95-96
    • Dick, R.S.1    Barold, S.S.2
  • 113
    • 0028966583 scopus 로고
    • Amiodarone-induced parkinsonism: A case report and pathogenetic discussion
    • Dotti M, Frederico A. Amiodarone-induced parkinsonism: a case report and pathogenetic discussion. Mov Disord 1995; 10: 233-4
    • (1995) Mov Disord , vol.10 , pp. 233-234
    • Dotti, M.1    Frederico, A.2
  • 114
    • 0022624892 scopus 로고
    • Buspirone: Review of its pharmacology and current perspective on its method of action
    • Eison AS, Temple DL. Buspirone: review of its pharmacology and current perspective on its method of action. Am J Med 1986 Suppl. 3B: 1-9
    • (1986) Am J Med , Issue.SUPPL. 3B , pp. 1-9
    • Eison, A.S.1    Temple, D.L.2
  • 115
    • 0027242157 scopus 로고
    • Persistent movement disorders induced by buspirone
    • LeWitt PA, Walters A, Hening W, et al. Persistent movement disorders induced by buspirone. Mov Disord 1993; 8: 331-4
    • (1993) Mov Disord , vol.8 , pp. 331-334
    • Lewitt, P.A.1    Walters, A.2    Hening, W.3
  • 116
    • 0027508276 scopus 로고
    • Parkinsonism in childhood after sodium valproate administration
    • Alvarez-Gomez MJ, Vaamonde J, Narbona J, et al. Parkinsonism in childhood after sodium valproate administration. Clin Neuropharmacol 1993; 16: 451-5
    • (1993) Clin Neuropharmacol , vol.16 , pp. 451-455
    • Alvarez-Gomez, M.J.1    Vaamonde, J.2    Narbona, J.3
  • 118
    • 0020532969 scopus 로고
    • Galactorrhea as a side-effect of domperidone
    • Cann PA, Read NW, Holdsworth CD. Galactorrhea as a side-effect of domperidone. BMJ 1983; 286: 1395-6
    • (1983) BMJ , vol.286 , pp. 1395-1396
    • Cann, P.A.1    Read, N.W.2    Holdsworth, C.D.3
  • 119
    • 0025733720 scopus 로고
    • Psychotic complications of long term levodopa treatment of Parkinson's disease
    • Friedman A, Sienkiewicz J. Psychotic complications of long term levodopa treatment of Parkinson's disease. Acta Neurol Scand 1991; 84: 111-3
    • (1991) Acta Neurol Scand , vol.84 , pp. 111-113
    • Friedman, A.1    Sienkiewicz, J.2
  • 120
    • 0025766667 scopus 로고
    • The management of the levodopa psychoses
    • Friedman JH. The management of the levodopa psychoses. Clin Neuropharmacol 1991; 12: 283-95
    • (1991) Clin Neuropharmacol , vol.12 , pp. 283-295
    • Friedman, J.H.1
  • 121
    • 0029161630 scopus 로고
    • Psychosis in advanced Parkinso's disease: Treatment with ondansetron, a 5-HT3 receptor antagonist
    • Zoldan J, Friedberg G, Livneh M, et al. Psychosis in advanced Parkinso's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995; 47: 1305-8
    • (1995) Neurology , vol.47 , pp. 1305-1308
    • Zoldan, J.1    Friedberg, G.2    Livneh, M.3
  • 122
    • 0023197778 scopus 로고
    • Preoperative management of the surgical patient with neurologic disease
    • Merli GJ, Bell RD. Preoperative management of the surgical patient with neurologic disease. Med Clin North Am 1987; 71 (3): 511
    • (1987) Med Clin North Am , vol.71 , Issue.3 , pp. 511
    • Merli, G.J.1    Bell, R.D.2
  • 124
    • 0024353822 scopus 로고
    • Acute postoperative confusion and hallucinations in PD
    • Golden WE, Lavender RC, Metzer WS. Acute postoperative confusion and hallucinations in PD. Ann Intern Med 1989; 111: 218-22
    • (1989) Ann Intern Med , vol.111 , pp. 218-222
    • Golden, W.E.1    Lavender, R.C.2    Metzer, W.S.3
  • 125
    • 7144246131 scopus 로고    scopus 로고
    • Neurologic syndromes and their disorders with their anesthetic implications
    • Albin MS, editor. New York (NY): McGraw Hill
    • Solomon D, Solomon D, Albin M. Neurologic syndromes and their disorders with their anesthetic implications. In: Albin MS, editor. Textbook of neuroanesthesia. New York (NY): McGraw Hill, 1997: 409-11
    • (1997) Textbook of Neuroanesthesia , pp. 409-411
    • Solomon, D.1    Solomon, D.2    Albin, M.3
  • 126
    • 0025759946 scopus 로고
    • Acute dystonia after alfentanil in untreated Parkinson's disease
    • Mets B. Acute dystonia after alfentanil in untreated Parkinson's disease. Anesth Analg 1991; 72: 557-8
    • (1991) Anesth Analg , vol.72 , pp. 557-558
    • Mets, B.1
  • 127
    • 0025065137 scopus 로고
    • Treatment of hypertensive crisis
    • Calhoun DA, Oparil S. Treatment of hypertensive crisis. N Engl J Med 1990; 323: 1177-83
    • (1990) N Engl J Med , vol.323 , pp. 1177-1183
    • Calhoun, D.A.1    Oparil, S.2
  • 129
    • 0029103428 scopus 로고
    • The serotonin syndrome: Implicated drugs, pathophysiology and management
    • Sporer KA. The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Saf 1995; 13: 94-104
    • (1995) Drug Saf , vol.13 , pp. 94-104
    • Sporer, K.A.1
  • 130
    • 0028143258 scopus 로고
    • Fluoxetine and the serotonin syndrome
    • Ruiz F. Fluoxetine and the serotonin syndrome. Ann Emerg Med 1994; 24: 983-5
    • (1994) Ann Emerg Med , vol.24 , pp. 983-985
    • Ruiz, F.1
  • 131
    • 0027965174 scopus 로고
    • Treatment of the serotonin syndrome with cyproheptadine
    • Lappin RI, Auchinloss EL. Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med 1994; 331: 1021-2
    • (1994) N Engl J Med , vol.331 , pp. 1021-1022
    • Lappin, R.I.1    Auchinloss, E.L.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.